CLAIMS

1. Use of an anti-LINGO-1 antibody in the manufacture of a medicament for the treatment of a central nervous system (CNS) demyelinating disease in a human subject, wherein the anti-LINGO-1 antibody is to be administered at a fixed dose of about 750 mg, and wherein the anti-LINGO-1 antibody comprises a heavy chain variable domain comprising heavy chain complementarity determining regions (CDRs) 1, 2 and 3 set forth in SEQ ID NO:6, 7 or 8, respectively, and a light chain variable domain comprising light chain CDRs 1, 2 and 3 set forth in SEQ ID NO:14, 15 or 16, respectively.

2. The use of claim 1, wherein the heavy chain variable domain comprises the amino acid sequence set forth in SEQ ID NO:5 and the light chain variable domain comprises the amino acid sequence set forth in SEQ ID NO:13.

3. The use of claim 1, wherein the anti-LINGO-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:275 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:276.

4. The use of any one of claims 1-3, wherein the anti-LINGO-1 antibody is to be administered intravenously.

5. The use of any one of claims 1-4, wherein the anti-LINGO-1 antibody is to be administered every four weeks.

6. The use of any one of claims 1-5, wherein the CNS demyelinating disease is multiple sclerosis.

7. The use of claim 6, wherein the human subject has a relapsing form of multiple sclerosis.

8. The use of claim 6, wherein the human subject has relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, secondary progressive multiple sclerosis, or active secondary progressive multiple sclerosis.

9. The use of any one of claims 1-5, wherein the CNS demyelinating disease is optic neuritis.

10. The use of any one of claims 1-9, wherein the anti-LINGO-1 antibody is to be administered in combination with an immunomodulatory agent.

11. The use of claim 10, wherein the immunomodulatory agent is an IFN-β 1 molecule, an antibody or fragment thereof against alpha-4 integrin, or dimethyl fumarate.

12. The use of any one of claims 1-11, wherein the use further comprises selecting a subject suitable for treatment with the anti-LINGO-1 antibody, wherein the subject suitable for treatment has, or is identified as having, 1, 2, 3, 4 or 5 of:

(i) a baseline Magnetization Transfer Ratio (MTR) in T2 lesion of less than or equal to about -.25 to about -.35 normalized MTR units (nMTRu);

(ii) a normalized MTR in T2 lesion of less than or equal to 0 nMTRu;

(iii) a disease duration of less than or equal to about 15 years to about 35 years;

(iv) a baseline diffuse tensor imaging-radial diffusivity (DTI-RD) in T2 lesion of less than or equal to about 0.9x10-3 mm^2/s to 1.0x10-3 mm^2/s; or

(v) a diffuse tensor imaging-radial diffusivity (DTI-RD) in a value of less than or equal to 1.2 $x10^{-3}$ mm^2/s.

13. The use of any one of claims 1-11, wherein the human subject is identified as having one, two, or all of the following prior to administration of the anti-LINGO-1 antibody:

(i) a baseline Magnetization Transfer Ratio (MTR) in T2 lesion of less than or equal to about -0.31 normalized MTR units (nMTRu);

(ii) a baseline diffuse tensor imaging-radial diffusivity (DTI-RD) in T2 lesion of less than or equal to about $0.95x10^{-3}$ mm^2/s; and

(iii) a disease duration of less than or equal to about 20 years.

14. A packaged composition comprising an anti-LINGO-1 antibody with instructions for administering said antibody at a fixed dose of about 750 mg, wherein the anti-LINGO-1 antibody comprises a heavy chain variable domain comprising heavy chain complementarity determining regions (CDRs) 1, 2 and 3 set forth in SEQ ID NO:6, 7 or 8, respectively, and a light chain variable domain comprising light chain CDRs 1, 2 and 3 set forth in SEQ ID NO:14, 15 or 16, respectively.

15. A packaged composition comprising a fixed dose of about 750 mg of an anti-LINGO-1 antibody, wherein the anti-LINGO-1 antibody comprises a heavy chain variable domain comprising heavy chain complementarity determining regions (CDRs) 1, 2 and 3 set forth in SEQ ID NO:6, 7 or 8, respectively, and a light chain variable domain comprising light chain CDRs 1, 2 and 3 set forth in SEQ ID NO:14, 15 or 16, respectively.